News for Editas Medicine, Inc. (0IFK.L)

Editas Medicine, Inc. (NASDAQ:EDIT) TD Cowen 45th Annual Health Care Conference March 3, 2025 2:30 PM ETCompany ParticipantsGilmore O'Neill - Chief...

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ( EDIT), a pioneering gene editing company focused on developing transformative medi

China-based WORK Medical Technology Group LTD (WOK) is up over 94 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Editas Medicine, Inc. (NASDAQ:EDIT) 43rd Annual JPMorgan Healthcare Conference Call January 15, 2025 2:15 PM ETCompany ParticipantsGilmore O'Neill -...

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ( EDIT), a leading gene editing company, today announced that the Company's Presiden

Brokerages downgrade gene editing company Editas to 'hold', shares slump 23%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of co

**media[487536]**

Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. ( E

Editas Medicine, Inc. (NASDAQ:EDIT) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ETCompany ParticipantsErick Lucera - Executive Vice...

Editas Medicine, Inc. (EDIT) experienced a significant stock drop of 5.13%, trading at $2.13 with a volume of 1.33438 million shares. The turnover rate was 1.62

Editas Medicine, Inc. (EDIT), a clinical-stage genome editing company, experienced a significant stock price drop of 5.24%. The stock is currently trading at $2

Editas Medicine stock hits 52-week low at $2.7 amid market challenges

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Editas Medicine, Inc.

**media[443277]**

Editas advances gene editing treatment for blood disorders

Editas Medicine, Inc. (EDIT), a company focused on genome editing technologies, experienced a significant stock drop of 5.09%, with shares priced at $2.96. The